Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies

G Ragia, VG Manolopoulos - European journal of clinical pharmacology, 2020 - Springer
Aim The COVID-19 pandemic caused by infection with the novel coronavirus SARS-CoV-2
is urging the scientific community worldwide to intense efforts for identifying and developing …

Candidate drugs against SARS-CoV-2 and COVID-19

DL McKee, A Sternberg, U Stange, S Laufer… - Pharmacological …, 2020 - Elsevier
Outbreak and pandemic of coronavirus SARS-CoV-2 in 2019/2020 will challenge global
health for the future. Because a vaccine against the virus will not be available in the near …

[HTML][HTML] Expression profiling meta-analysis of ACE2 and TMPRSS2, the putative anti-inflammatory receptor and priming protease of SARS-CoV-2 in human cells, and …

E Gkogkou, G Barnasas, K Vougas, IP Trougakos - Redox biology, 2020 - Elsevier
Abstract Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and has resulted in hundreds of thousands of …

Epithelial and Endothelial Expressions of ACE2: SARS-CoV-2 Entry Routes.

C Guney, F Akar - Journal of pharmacy & pharmaceutical sciences …, 2021 - avesis.gazi.edu.tr
Angiotensin converting enzyme 2 (ACE2) is a main receptor for SARS-CoV-2 entry to the
host cell. ACE2 is one of the key enzymes in renin-angiotensin system and plays a vital role …

Potential COVID‐19 therapeutic approaches targeting angiotensin‐converting enzyme 2; an updated review

S Zanganeh, N Goodarzi, M Doroudian… - Reviews in Medical …, 2022 - Wiley Online Library
COVID‐19 has spread swiftly throughout the world posing a global health emergency. The
significant numbers of deaths attributed to this pandemic have researchers battling to …

An enzymatic TMPRSS2 assay for assessment of clinical candidates and discovery of inhibitors as potential treatment of COVID-19

JH Shrimp, SC Kales, PE Sanderson… - ACS pharmacology & …, 2020 - ACS Publications
SARS-CoV-2 is the viral pathogen causing the COVID19 global pandemic. Consequently,
much research has gone into the development of preclinical assays for the discovery of new …

A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor

M Oz, DE Lorke, N Kabbani - Pharmacology & therapeutics, 2021 - Elsevier
The recent emergence of coronavirus disease-2019 (COVID-19) as a global pandemic has
prompted scientists to address an urgent need for defining mechanisms of disease …

A comprehensive review on potential therapeutics interventions for COVID-19

H Chugh, A Awasthi, Y Agarwal, RK Gaur… - European Journal of …, 2021 - Elsevier
COVID-19 is an infectious respiratory disease caused by SARS-CoV-2, a new beta
coronavirus that emerged in Wuhan, China. Being primarily a respiratory disease, it is highly …

Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19

R Poduri, G Joshi, G Jagadeesh - Cellular signalling, 2020 - Elsevier
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense,
single-stranded RNA virus that causes the potentially lethal Covid-19 respiratory tract …

Hiding in plain sight: an approach to treating patients with severe COVID-19 infection

DS Fedson, SM Opal, OM Rordam - MBio, 2020 - Am Soc Microbiol
Patients with COVID-19 infection are at risk of acute respiratory disease syndrome (ARDS)
and death. The tissue receptor for COVID-19 is ACE2, and higher levels of ACE2 can protect …